Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 7/20 | 0.72 |
| ▸ | KDR | P35968 | 7/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.59 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.59 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.59 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.54 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.53 |
| ▸ | FLT3 | P36888 | 3/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.52 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 3/20 | 0.50 |
| ▸ | CSF1R | P07333 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116211 | 1.00 | RET (0.72) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL2114263 | 0.86 | RET (0.65) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL30454169 | 0.86 | RET (0.65) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL2114264 | 0.86 | RET (0.65) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL2118582 | 0.84 | KDR (0.70) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL2118577 | 0.84 | KDR (0.70) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL30454095 | 0.84 | KDR (0.70) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL13081086 | 0.84 | RET (1.00) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL6396736 | 0.81 | FLT1 (0.76) | RETKDRMEN1KMT2APDPK1 | |
| SCHEMBL6396732 | 0.81 | FLT1 (0.76) | RETKDRMEN1KMT2APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4599890-A2 | SUNITINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2025-08-13 | — | — | EP | disclosed |
| CN-113181362-B | Medicament for preventing and/or treating amyotrophic lateral sclerosis | 国立大学法人京都大学 | 2023-06-13 | — | — | CN | disclosed |
| EP-3789027-A1 | BOSUTINIB, SUNITINIB, TIVOZANIB, IMATINIB, NILOTINIB, REBASTINIB OR BAFETINIB FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2021-03-10 | — | — | EP | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| EP-3246046-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | Kyoto University (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | NEKTAR THERAPEUTICS (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010120387-A1 | OLIGOMER-PROTEIN TYROSINE KINASE INHIBITOR CONJUGATES | NEKTAR THERAPEUTICS (US) | 2010-10-21 | — | — | WO | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6797725-B2 | SUCH AS 4-METHYL-5-(2-OXO-1,2-DIHYDROINDOL-3-YLILDENEMETHYL)-1H-PYRROLE-2-CARBOXYLIC ACID FOR PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS; ANTICANCER AGENTS | SUGEN, INC. | 2004-09-28 | — | — | US | disclosed |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN, INC. | 2004-09-23 | — | — | US | disclosed |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2004-04-01 | — | — | US | disclosed |
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2003-11-20 | — | — | US | disclosed |
| US-6573293-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. | 2003-06-03 | — | — | US | disclosed |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | SUGEN. INC. | 2003-05-29 | — | — | US | disclosed |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PHARMACIA & UPJOHN COMPANY LLC | 2002-10-24 | — | — | US | disclosed |
| EP-1233943-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | Sugen, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216410-A1 | Combination therapy for the treatment of cancer | PTGS2, PTGES2, PTGFR | RET 48/4885KDR 498/4885MEN1 3129/4885 |
| US-20040186161-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | RET 385/4885KDR 1081/4885MEN1 3621/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | RET 355/4885KDR 648/4885MEN1 4752/4885 |
| US-20030100555-A1 | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives | PLK2, CDK2, PDPK1 | RET 385/4885KDR 1081/4885MEN1 3621/4885 |
| US-20120094998-A1 | Oligomer-Protein Tyrosine Kinase Inhibitor Conjugates | PTK2B, ERBB2, FRK | RET 73/4885KDR 395/4885MEN1 2122/4885 |
| US-20040063773-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | RET 485/4885KDR 1372/4885MEN1 3826/4885 |
| US-20020156292-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | RET 485/4885KDR 1372/4885MEN1 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.